FDA Holds To High Standards For Insomnia Drugs With Second “Complete Response” For Transcept’s Intermezzo
This article was originally published in Pharmaceutical Approvals Monthly
FDA’s second “complete response” letter for Transcept Pharmaceuticals’s Intermezzo continues the strict scrutiny the agency has given recent candidates for sleep maintenance insomnia indications.
You may also be interested in...
FDA will conduct an advisory committee early in 2012 to discuss how to assess the cardiovascular risk of weight-loss drugs, Orexigen revealed June 3 in announcing the firm will halt development in the U.S. of its obesity medication Contrave.
Results from a driving impairment study strengthen the case for approval, the company says.
In its second "complete response" letter for the chronic insomnia drug, FDA says Silenor fails to meet approval standards.